LungQ Software

by Thirona Corporation  · Based in Netherlands → — AI-Powered Lung Image Analysis for Precision Pulmonary Care
Pulmonology Radiology

Contact-for-pricing
Regulatory Status Disclosed

Overview

Thirona’s LungQ® software offers advanced, AI-powered analysis of thoracic CT scans, providing comprehensive quantitative insights for the detection, evaluation, and treatment planning of various lung diseases. Leveraging deep learning models, LungQ® performs high-fidelity segmentation and quantification of anatomical structures within the lungs, including lobes, segments, subsegments, airways, blood vessels, and fissures.

The software delivers reproducible CT values for pulmonary tissue, which is crucial for objective support in diagnosis, patient selection for treatment, and longitudinal monitoring of disease progression and treatment efficacy. LungQ® analyses extend to detailed airway morphology (identifying bronchial wall thickness, dilatation, narrowing, and mucus impaction), vascular morphology (assessing pulmonary arterial and venous volume changes), and parenchymal analysis (characterizing texture patterns and estimating chronic perfusion defects, known as PXT).

Recent versions, such as LungQ® 4, have expanded capabilities to include enhanced peripheral airway segmentation, estimation of chronic perfusion defects from CT, and post-treatment detection of endobronchial implants. This technology is designed to support physicians in making more precise diagnoses, personalizing treatment strategies, guiding interventional procedures like bronchoscopy, and accelerating respiratory clinical trials.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-powered analysis of thoracic CT scans
  • Automated segmentation of pulmonary segments and subsegments
  • Volumetric analysis and quantification of anatomical structures
  • Airway morphology analysis (bronchial wall thickness, dilatation, narrowing, mucus impaction)
  • Vascular morphology analysis (pulmonary arterial and venous volume changes)
  • Fissure completeness analysis
  • Parenchymal analysis (texture patterns, estimated chronic perfusion defects - PXT)
  • Post-treatment detection of endobronchial implants
  • Provides reproducible CT values for pulmonary tissue
  • One-page report with severity scores for emphysematous lung tissue and fissure completeness

Use Cases

  • Diagnosis and evaluation of lung diseases
  • Treatment planning for lung interventions (e.g., lung volume reduction, bronchoscopy)
  • Follow-up and longitudinal monitoring of disease progression
  • Respiratory clinical trials and drug development
  • Patient phenotyping and selection for personalized medicine
  • Guidance for navigational bronchoscopy

What Physicians Need to Know

Key Capabilities
AI-powered analysis of thoracic CT scans, including advanced segmentation of pulmonary segments and subsegments, enhanced peripheral airway segmentation, and quantification of anatomical volumes, disease distributions, airway morphology, vascular morphology, and fissure completeness. It also provides estimated chronic perfusion defects (PXT) and post-treatment detection of endobronchial implants. The software supports analysis of COVID-related abnormalities and offers detailed bronchial and vascular analysis (e.g., wall thickness, dilatation, narrowing, mucus impaction, vessel volumes).
Clinical Utility
Supports diagnosis, evaluation, and treatment planning for various lung diseases such as COPD, emphysema, asthma, cystic fibrosis, and lung cancer. It aids in precise access planning for navigational bronchoscopy, provides consistent anatomical referencing for airway abnormalities, and assists in treatment target selection for lung volume reduction therapy. LungQ enables personalized treatment planning, monitoring of disease progression, and post-treatment evaluation of endobronchial implants, aiming to improve operational efficiency and accelerate diagnosis.
Integration Options
Available for integration via AI marketplaces or distribution platforms, such as the Blackford Platform. It can also be deployed as a stand-alone web-based solution or locally on dedicated hardware. Analysis can be triggered automatically after image acquisition or on-demand.
Compliance Status
FDA 510(k) cleared (LungQ 3.0.0 in January 2024, LungQ 4 in October 2025). CE Certified (MDR Class IIa for LungQ Clinical Suite, LungQ v2.y.z Class IIb). Holds MDSAP, ISO 13485, and ISO 27001 certifications. Compliant with EU MDR 2017/745 and U.S. FDA Quality System Regulation (21 CFR Part 820). Approved for clinical use in Europe, the UK, and Australia.
Pricing Model
Not explicitly detailed, but indicated to be based on the 'Number of analyses'.
User Experience
Designed to be user-friendly and faster than traditional manual methods, particularly noted for its automated analysis in Cystic Fibrosis (PRAGMA-AI) which can process scans in seconds. Aims to make advanced pulmonary procedures easier to perform.
Support Quality
Thirona emphasizes a strong commitment to customer success and reliable project delivery. Their quality and regulatory system is built for continuous improvement, with ongoing audits, certifications, and refinement through collaboration with MedTech and pharma partners.
Implementation Complexity
Deployment options include local installation on dedicated hardware or integration through AI platforms. The analysis can be automated or on-demand. Processing time for analysis is stated as typically over 10 minutes.
Evidence Base
Validated in over 200 global publications and built on 10 years of clinical trials. Studies have demonstrated excellent accuracy and reliability, with quantitative information comparable to SPECT-CT for perfusion analysis. Used in imaging-based exploratory research and clinical trials for drug development, and shown to provide accurate disease progression management with consistent, reproducible measurements.
Physician Tip

LungQ offers highly precise, quantitative CT analysis for a broad spectrum of lung diseases, enabling personalized treatment planning and longitudinal monitoring. Its FDA and CE clearances, coupled with extensive validation, provide a strong foundation for clinical trust. Physicians should leverage its advanced segmentation and quantification capabilities for detailed insights into airway, vascular, and parenchymal abnormalities, especially for interventional pulmonology and complex respiratory disease management. The ability to detect subtle changes and provide reproducible measurements is crucial for tracking disease progression and assessing treatment efficacy. Consider its integration with existing PACS/EMR systems via AI marketplaces for streamlined workflows.

LungQ is designed for flexible integration, supporting deployment via AI marketplaces and distribution platforms (e.g., Blackford Platform), as well as stand-alone web-based access or local hardware installation. This flexibility allows healthcare providers to integrate the AI tool into their existing imaging workflows, whether through automated triggers post-acquisition or on-demand user initiation. Compatibility with DICOM input and various output formats (HTML, PDF, JSON, segmentation overlays) facilitates data exchange and reporting.

Details

Category Oncology AI, Radiology & Imaging AI
Pricing Contact-for-pricing
DeploymentSoftware solution, designed for integration into clinical workflows and systems.
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

LungQ first received U.S. FDA 510(k) clearance for version 1.1.0 in 2018 (K173821). Subsequent versions, including LungQ® 3.0.0 (January 2024) and LungQ® 4 (October 2025), have also received FDA clearance, expanding its AI-powered capabilities for lung image analysis.

Integrations
EHR Not specified
Specialties Pulmonology, Radiology

What the Web Says

LungQ Software, developed by Thirona, is an AI-powered solution for analyzing thoracic CT images to detect and quantify lung anomalies. It aims to improve diagnosis, patient monitoring, and treatment planning for various lung diseases, including cystic fibrosis, COPD, and lung cancer. The software has received FDA 510(k) clearance for multiple versions and is used in over 600 hospitals globally.

Overall: Positive

Strengths

  • Fast and fully automated analysis of CT scans, reducing human intervention and time.
  • Accurate detection and quantification of lung damage, including peripheral airway segmentation and estimation of chronic perfusion deficits.
  • Supports personalized treatment planning and monitoring of disease progression with quantitative measurements.
  • Aids in diagnosis and documentation of pulmonary tissue images.
  • Enhances precision, accuracy, and efficiency of bronchoscopic and surgical lung interventions.
  • Validated in numerous publications and studies, demonstrating high diagnostic performance.

Limitations

  • No specific cons were found in the provided search results from physicians, healthcare IT, tech reviewers, Reddit, G2, or Capterra regarding LungQ Software. The search results for Reddit, G2, and Capterra primarily discussed other software with similar names (e.g., LingQ, LightningQ, PracticeQ) or general AI in radiology, not Thirona's LungQ.

Based on reviews from: The Silicon Review, Diagnostic Imaging, AuntMinnie, DAIC, Blackford Analysis

Last updated: 2026-07-20

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate LungQ Software

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Respiratory Therapy
FDA Clears AI Software for Lung Segment Analysis in CT Scans | Respiratory Therapy
Thirona received FDA 510(k) clearance for LungQ (v3.0.0), an AI-based clinical software that automatically segments pulmonary segments and subsegments in CT scans, aiding in diagnosis and treatment planning for lung diseases.
2024-01
ICE Magazine
Thirona receives FDA 510(k) Clearance for LungQ Software - ICE Magazine
Thirona's LungQ (v3.0.0) software, cleared by the FDA, uses AI to automatically segment lung anatomy from CT scans, providing crucial information for diagnosing and treating conditions like COPD and lung cancer.
2024-02
Diagnostic Imaging
FDA Clears Updated AI Software for Lung CT | Diagnostic Imaging
The FDA granted 510(k) clearance for LungQ 3.0.0, an updated AI-powered software for lung CT scans, which improves visualization and assessment of lung structures to enhance interventional procedures and diagnosis.
2024-01
Business Wire
Thirona receives FDA 510(k) Clearance for LungQ v3.0.0 Software to Power AI Analysis of Chest CT Images - Business Wire
Thirona announced FDA 510(k) clearance for LungQ v3.0.0, an AI-based software for chest CT image analysis, enabling automated segmentation of pulmonary segments and subsegments for improved diagnosis and personalized treatment.
2024-01
HMP Global Learning Network (Respiratory)
Thirona Announces Partnerships to Enhance AI-based Lung Image Analysis
Following FDA approval for LungQ (v3.0.0), Thirona has announced multiple partnerships to enhance AI-based lung image analysis, aiming to enable breakthroughs in precision medicine for pulmonary diseases.
2024-06
The Silicon Review
Thirona launches new LungQ software to analyze CF airway problems speedily
Thirona launched new LungQ software, incorporating the PRAGMA-AI algorithm, to quickly detect and quantify lung anomalies in cystic fibrosis (CF) patients from CT scans, improving diagnosis and treatment planning.
2021-04
Cystic Fibrosis News Today
New LungQ Software Can Analyze CF Airway Problems in Seconds, Thirona Says
Thirona's new LungQ software, powered by the PRAGMA-AI algorithm, offers fast and automated detection and quantification of lung anomalies in cystic fibrosis patients, aiding in treatment decisions and disease monitoring.
2021-04
BMC Pulmonary Medicine (via PMC)
CT-Based Commercial Software Applications: Improving Patient Care Through Accurate COPD Subtyping - PMC
Thirona's LungQ software is highlighted for its capabilities in quantifying anatomical volumes, disease distribution, airway and vascular morphology, and fissure completeness from thoracic CT images, aiding in COPD subtyping.
2022-04

Videos

Product demos, reviews, and walkthroughs for LungQ Software.

View all on YouTube

Frequently Asked Questions

LungQ is an AI-powered software developed by Thirona designed for advanced analysis of thoracic CT scans. It provides quantitative insights to support the diagnosis, patient selection for treatment, treatment planning, and follow-up examinations for various lung diseases such as COPD, emphysema, asthma, cystic fibrosis, and COVID-19. The software offers reproducible CT values for pulmonary tissue, aiding in more precise diagnosis and personalized treatment planning.
Yes, LungQ Software is regulatory compliant for clinical use. The latest version, LungQ 4, has received FDA 510(k) clearance in the United States, and it is also CE-certified for clinical use in Europe, the UK, and Australia.
LungQ leverages advanced deep learning models to offer enhanced peripheral airway segmentation, estimation of chronic perfusion defects directly from CT images (PXT feature), and post-treatment detection of endobronchial implants. It also provides precise anatomical segmentation down to subsegments, analyzes airway and vascular morphology, assesses fissure completeness, and performs volumetric analysis to guide interventions like navigational bronchoscopy.
While LungQ offers significant advancements, general limitations for AI in radiology can include the potential for bias and the need for robust validation across diverse patient populations. Integration challenges might involve ensuring compatibility with existing PACS environments and adapting clinical workflows to incorporate AI-generated insights.
While specific details on LungQ's data privacy protocols are not extensively detailed in public searches, Thirona emphasizes robust software and processes to ensure maximum data security, especially when integrated with platforms like Blackford Enterprise Platform. Generally, FDA-cleared and CE-certified medical software adheres to strict data protection regulations to safeguard sensitive patient information.
Specific pricing for LungQ Software is not publicly disclosed. However, similar deep-learning computer-aided lung nodule detection software often utilizes pricing models such as pay-per-use, one-off perpetual software licenses, or yearly subscriptions. Healthcare facilities should anticipate costs associated with software licensing, integration, hosting, monitoring, and ongoing support.
Yes, several other AI solutions offer lung CT analysis capabilities that physicians might consider. Competitors in this space include Infervision (InferRead CT Lung), DeepHealth (Chest Suite), Coreline (AVIEW LCS), and Qure AI (qCT-Lung & qCT LN Quant), each offering various features for nodule detection, characterization, and longitudinal analysis.

Related Tools

Surgical Reality Viewer
Surgical Reality
Oncology AI
Surgical Reality offers CE- and FDA-certified AI-powered 3D medical imaging and surgical planning software that transforms CT scans into patient-specific 3D models for thoracic surgery, enhancing precision in complex lung procedures.
Cancer Copilot
Color Health
Oncology AI
Color Health's Cancer Copilot, built with OpenAI, helps oncologists and clinicians identify and order workup needs for recently diagnosed patients, aiming to speed up time to cancer treatment. This AI tool is designed to expand cancer expertise, speed decisions, and improve care, reducing a two-hour clinical task to 10 minutes with over 95% validated accuracy.
Cercare Medical Oncology Virtual Expert
Cercare Medical
Neurology AI
Cercare Medical's Oncology Virtual Expert is an AI-powered brain tumor segmentation module that provides fast, consistent, and semi-automated tumor analysis from standard MRI data, designed for on-premise deployment within existing clinical radiology workflows.
Synapse Lung Nodule AI
Fujifilm Corporation
Oncology AI
Fujifilm's Synapse Lung Nodule AI is an AI software algorithm for detecting pulmonary nodules on CT imaging, aiming to support early detection and treatment of lung cancer.
RadOncAI
Informai (for RadOncAI product) / Global Network for AI in Radiation Oncology (for RadoncAI.net)
Oncology AI
RadOncAI is an AI solution by Informai designed to optimize and enhance radiation oncology workflows, improving efficiency and accuracy in treatment planning and delivery.
FAITH project (Fatigue Therapy – AI-supported Diagnosis and Therapy of Tumour-associated Fatigue Syndrome)
Fimo Health GmbH (Consortium Leader)
Mental & Behavioral Health AI
The FAITH project is developing an AI-based solution for the diagnosis and therapy of tumor-associated fatigue syndrome in cancer patients. It uses wearable sensors, a smartphone app, and artificial intelligence to provide individualized therapy recommendations and monitor mental health.

See all Oncology AI tools →

More from Thirona

RetCAD
Thirona
Ophthalmology AI
RetCAD is a CE-certified AI software product from Thirona that analyzes color fundus images for the presence of Age-related Macular Degeneration (AMD) and Diabetic Retinopathy (DR), aiding in early detection and grading of these vision-threatening conditions.

View company profile →

Suggest an Edit → | Last Verified: 2026-04-19 | First Added: 2026-04-19

Investors who backed LungQ Software

Funded through the company that built this tool.

AI Tool Finder
AI-powered search. Results may not be comprehensive.